Abbott in Pact With FDA on Steps to Reopen Baby-Formula Plant
- Regulators outline steps to reopen Abbott plant in Michigan
- New FDA guidelines on imports are aimed at easing shortage
The Abbott manufacturing facility in Sturgis, Michigan.
Photographer: Jeff Kowalsky/AFP/Getty Images
This article is for subscribers only.
The Biden administration took a series of domestic and international steps to channel more infant formula to the US market, aiming to blunt a shortage of the vital supplies that has stressed parents and created political uproar.
Health officials and Abbott Laboratories reached a pact that will allow the company to resume making formula again at a troubled plant in Michigan that was closed after it was linked to infection. The Food and Drug Administration late Monday laid out new standards for importing formula made by overseas companies, and the White House vowed to help smooth logistics to get formula back on shelves faster.